

## **CORPORATE NEWS**

MeVis Medical Solutions AG Caroline-Herschel-Straße 1 28359 Bremen Germany

Phone: +49 421 224 95 0 Fax: +49 421 224 95 999 E-mail: ir@mevis.de

## MeVis Medical Solutions AG: Approval of the domination and profit and loss transfer agreement with the VMS Deutschland Holdings GmbH

**Bremen, September 30, 2015** – Yesterday's extraordinary general meeting of MeVis Medical Solutions AG resolved to approve the domination and profit and loss transfer agreement between the VMS Deutschland Holdings GmbH as the controlling company and MeVis Medical Solutions AG as the controlled company. The proposed resolution was approved by a majority of 98.40 % of all shareholders present or represented. In order to become effective, the domination and profit and loss transfer agreement requires registration with the commercial register.

Marcus Kirchhoff, CEO of MeVis Medical Solutions AG, pointed out: "The approval of the domination and profit and loss transfer agreement is an important milestone for the future of MeVis. It allows a close cooperation between MeVis and the Varian Group as well as the implementation of standardized organizational structures and strategies in this legal framework." Dr. Robert Hannemann, CFO of the Company, adds: "The contract also provides special protection measures for minority shareholders, such as the entitlement to receive an annual compensation of EUR 1.13 gross / EUR 0.95 net per share or the option to transfer MeVis shares to the VMS at a price of EUR 19.77."

\*

**MeVis Medical Solutions AG** was founded in 1997 and is one of the world's leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.

Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis' products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.